Please assess the completion status of the following clinical trial:

Trial Title: Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmation of metastatic or recurrent renal cell carcinoma~Exclusion Criteria:~* Certain types of previous anti-cancer therapy for Renal Cell Carcinoma~* Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes~* Patients with a history of poorly controlled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Cediranib placebo
- 2 (Type: EXPERIMENTAL): Cediranib

Based on this trial design, predict the completion outcome and termination type (if applicable).